Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea was listed on the SIX Swiss Stock Exchange in 2004 and is well funded through its key near-term milestones. Revenue growth will be driven from its two marketed anti-infectives: Cresemba (antifungal – for invasive mould infections) and Zevtera (antibiotic – for hospital infections), which are commercialised
29 May 2019
Basilea Pharmaceutica - Executive interview – Basilea Pharmaceutica
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Executive interview – Basilea Pharmaceutica
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
29 May 2019 -
Author:
Dr Susie Jana -
Pages:
2
Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea was listed on the SIX Swiss Stock Exchange in 2004 and is well funded through its key near-term milestones. Revenue growth will be driven from its two marketed anti-infectives: Cresemba (antifungal – for invasive mould infections) and Zevtera (antibiotic – for hospital infections), which are commercialised